← ANALYST RATINGS · TIPRANKS
Cartesian Therapeutics (RNAC): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy0 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $32.60, the highest $44.00, the lowest $16.00. The average is +419.9% from the last price of $6.27.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.50 → $6.00−20.0% | Hold | −4.3% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.00 → $6.00−14.3% | Sell | −4.3% | Downgrade | 15.10.26on TipRanks 02:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.50 → $6.00−20.0% | Hold | −4.3% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.50 → $6.00−20.0% | Hold | −4.3% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.50 → $6.00−20.0% | Hold | −4.3% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 → $6.00−20.0% | Hold | −4.3% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $25.00 | Buy | +298.7% | Reiterated | 30.09.26on TipRanks 06:55 | −0.2%next day 0.0% · 5 days −9.3% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $44.00 | Buy | +601.8% | Reiterated | 29.09.26on TipRanks Sep 30 06:30 | +0.6%next day −0.2% · 5 days −8.7% | ↗ |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | $40.00 | Buy | +538.0% | Reiterated | 29.09.26on TipRanks 12:45 | +0.6%next day −0.2% · 5 days −8.7% | ↗ |
| Martin Fan★★★★★★★★★★#177 · hits 87% · avg +94.8% | Wedbush | $38.00 | Buy | +506.1% | Reiterated | 18.08.26on TipRanks 08:45 | +0.9%next day +13.8% · 5 days +13.0% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $16.00 | Buy | +155.2% | Reiterated | 06.08.26on TipRanks Aug 7 14:25 | +5.1%next day +0.4% · 5 days −1.7% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 06.08.26on TipRanks Aug 7 04:00 | +5.1%next day +0.4% · 5 days −1.7% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | — | Buy | — | Reiterated | 27.05.26on TipRanks 10:15 | +7.5%next day +3.5% · 5 days −10.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Cartesian Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $32.60 at a price of $7.21 (+352.1%); now: $32.60 at $6.27 (+419.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 13 | 10 | 11 | 10 | 9 |
| Buy | 4 | 3 | 3 | 1 | 1 | 1 |
| Hold | 2 | 1 | 1 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.01 (from $-1.13 to $-0.95). Last quarter: $0.46.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Cartesian Therapeutics
- CEO: Carsten Brunn
- Employees: 75
- 7495 New Horizon Way, Frederick, MD, 21703, US
- cartesiantherapeutics.com
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Data from the stock’s TipRanks forecast page, read 61 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗